Lunit, recognized as one of the 100 most promising private AI companies in the world by CB Insights, will showcase Opsy for Pathology, a product line based on winning algorithm of MICCAI Tumor Proliferation Assessment Challenge 2016 at the Henry B. Gonzales Convention Center in San Antonio, TX, on March 4 through March 10, 2017.
Named after the investigative nature of its algorithms, Opsy seeks to provide valuable information, both diagnostic as well as predictive, for pathologists and researchers alike.
Lunit will exhibit the first public demonstration of Opsy for Pathology for breast and prostate cancer at booth #222.
Lunit's goal is to develop AI-powered state-of-the-art diagnostic software that helps pathologists diagnose better and faster, as well as discover novel histopathologic biomarkers with high clinical impact.
Lunit is looking for worldwide partnership with healthcare providers, scanner manufacturers, and platform vendors. To schedule a demonstration of Opsy and/or meeting at the upcoming USCAP 2017, please reach out via email to firstname.lastname@example.org.
Feb. 28, 2017, 2:40 a.m.